Colorectal Cancer Therapeutics Market, By Type (Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors, and Others), By Drug Class (Immunotherapy, Chemotherapy, and Targeted Therapy), By Sales Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), By Top Selling Drugs (5-Flurorouracil, Capecitabine, Irinotecan, Oxaliplatin, and Trifluridine & Tipiracil) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Report Code: PMI488522 | Publish Date: May 2024 | No. of Pages: 178

Colorectal Cancer Therapeutics Market Overview

Colorectal cancer is a type of malignant tumor on the inner walls of large intestine. This is due to the uncontrollable growth of cells which have the ability to affect or spread to other parts of the body. The common causes of such cancer are inflammatory bowel disease as well as due to genetic inheritance. Symptoms of colorectal cancer includes diarrhea or constipation, fatigue, weakness, changing pattern of bowel habits, red or dark blood in stool, cramps, shortness of breath, weight loss, abdominal pain, and bloating. These symptoms may arise after the several years of the tumor. This cancer is divided into various stage on the basis of its affection: stage 0, cancer detect on the early stage, stage 1, cancer present in the inner walls of colon, stage 2, cancer spreading through muscle wall of colon, stage 3, cancer spreads to lymph nodes, stage 4 (severe condition), cancer spreads to other parts of body. There are different tactics in order to deal with colorectal cancer. The best treatment to get rid of it is surgical resection, which involves removing the tumor completely through surgery and reconstructing the bowel, if possible, so that it gets back to its normal function or near normal. Other treatment are radiation therapy and chemotherapy. The Food and Drug Administration (FDA) has recently approved encorafenib (Braftovi) for the treatment of some patients suffering from colorectal cancer. The colorectal cancer therapeutics market accounted for US$ 9.8 billion in 2020 and is estimated to be US$ 16.36 billion by 2030 and is anticipated to register a CAGR of 5.3%.

Colorectal Cancer Therapeutics Market Dynamics

Rising cases of colorectal cancer globally

The increasing prevalence of colorectal cancer globally which is the key factor driving the growth of colorectal cancer therapeutics market. This is because of increasing cases, demand of advance therapeutics etc. are boosting the demand of such treatments. Thus, increasing research on such cancers and development of various drugs in laboratories are expected to propel the growth of this particular market. Additionally, colorectal cancer is more common among geriatric population and is projected to have a positive impact on the growth of such market. Moreover, rising among population and demand of effective solutions for colorectal cancer is anticipated to drive the growth of this specific market. Increasing demand of budget friendly therapies is fueling growth of global colorectal cancer therapeutics market.

However, high cost of treatments and fear of such surgeries are the major root cause which can restrain the growth of the target market. Side effects of such therapies are very dangerous which in turn hamper the growth of this particular market.   

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Colorectal Cancer Therapeutics Market Segmentation

The colorectal cancer therapeutics market is segmented based on type, drug class, sales channel, top selling drugs, and region.

On the basis of type, the colorectal cancer therapeutics market is segmented into colorectal adenocarcinoma, gastrointestinal carcinoid tumors and others. Based on drug class, the target market is segmented into immunotherapy, chemotherapy, and targeted therapy. On the basis of sales channel, the target market is segmented into hospitals pharmacies, retail pharmacies, online pharmacies and others. On the basis of top selling drugs, the target market is segmented into 5-Flurorouracil, Capecitabine, Irinotecan, Oxaliplatin, and Trifluridine & Tipiracil.

Regional Insights:

colorectal cancer therapeutics market accounted for US$ 9.8 billion in 2020 and is estimated to be US$ 16.36 billion by 2030 and is anticipated to register a CAGR of 5.3%. On region the colorectal cancer therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is currently dominating the global colorectal cancer therapeutics market because of rising geriatric population, advanced technologies, highest investment in pharmaceuticals and R&D department etc. are driving the market in this region. Asia Pacific is holding the second position in this market due to increasing number of colorectal cancer cases, unhealthy diet practices, changing lifestyle, changing food quality etc. are increasing cases of such cancer which in turn boost the growth of market in this region.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Report Scope:

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2020

Market representation

Revenue in USD Billion & CAGR from 2020 – 2030

Market Segmentation

By Type- Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors, and Others.

By Drug Class– Immunotherapy, Chemotherapy, and Targeted Therapy

By Sales Channel– Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, and Others

By Top Selling Drugs- 5-Flurorouracil, Capecitabine, Irinotecan, Oxaliplatin, and Trifluridine & Tipiracil

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the global colorectal cancer therapeutics market report based on type, drug class, sales channel, top selling drugs, and region.

Colorectal Cancer Therapeutics Market, By Region:

  • North America
    • Middle East & Africa
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa
    • Latin America
        • Brazil
        • Mexico
        • Rest of Latin America
    • Asia Pacific
        • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Europe
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
      • U.S.
      • Canada

Colorectal Cancer Therapeutics Market Key Players

The key players operating in the colorectal cancer therapeutics market includes Pfizer Inc., Teva Pharmaceutical Industries Ltd, Hikma Pharmaceuticals Plc, Amneal Pharmaceuticals Inc., Amgen Inc., Bayer AG, Bristol-Myers Squibb, Eli Lilly and Company, Merck & Co., Inc., Biocon Ltd. Prominent players operating in the target market are focusing on the strategic partnerships as well as launching of the products in order to gain competitive edge in the target market. In 2021, Natco Pharma introduced a novel fixed-dose combination of Trifluridine and Tipiracil, used to treat advanced colorectal and gastric cancer, in India.

Emerging Drugs:

                      Drug Name

                          Description

                Patritumab Deruxtecan

It is comprised of a human anti-HER3 antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a stable tetrapeptide-based cleavable linker.

                         Adagrasib

It is an investigational, highly selective and potent, oral small molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation.

                      Etrumadenant

The first dual A2a/A2b adenosine receptor antagonist in the clinic, is designed to maximally inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes (mainly CD8+ T cells and NK cells) and myeloid cells (dendritic cells, macrophages), mediated by A2aR and A2bR, respectively.

Colorectal Cancer Therapeutics Market Company Profile

  • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Teva Pharmaceutical Industries Ltd
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Hikma Pharmaceuticals Plc
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Amneal Pharmaceuticals Inc
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Amgen Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Bayer AG
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Bristol-Myers Squibb
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Merck & Co., Inc
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Biocon Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies

Colorectal Cancer Therapeutics Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for Colorectal Cancer Therapeutics Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Type
      • Market Snippet, By Drug Class
      • Market Snippet, By Sales Channel
      • Market Snippet, By Top Selling Drugs
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Market Segmentation, By Type 2020 – 2030, (US$ Bn)
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Colorectal Adenocarcinoma
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Gastrointestinal Carcinoid Tumors
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
  6. Market Segmentation, By Drugs Class 2020 – 2030, (US$ Bn)
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Immunotherapy
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Chemotherapy
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Targeted Therapy
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
  7. Market Segmentation, By Sales Channel 2020 – 2030, (US$ Bn)
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Hospitals Pharmacies
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Retail Pharmacies
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Online Pharmacies
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    •  
  8. Market Segmentation, By Top Selling Drugs 2020 – 2030, (US$ Bn)
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • 5-Flurorouracil
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Capecitabine
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Irinotecan
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Oxaliplatin
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Trifluridine & Tipiracil
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030

 

  1. Global Market, By Region, 2020 – 2030, (US$ Bn)
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Bn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Drug Class, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Sales Channel, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Top Selling Drugs, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Bn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Drug Class, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Sales Channel, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Top Selling Drugs, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Bn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Drug Class, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Sales Channel, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Top Selling Drugs, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Bn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Drug Class, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Sales Channel, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Top Selling Drugs, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Bn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Drug Class, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Sales Channel, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Top Selling Drugs, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  2. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  3. Company Profiles
  • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Teva Pharmaceutical Industries Ltd
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Hikma Pharmaceuticals Plc
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Amneal Pharmaceuticals Inc
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Amgen Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Bayer AG
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Bristol-Myers Squibb
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Merck & Co., Inc
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Biocon Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  1. The Last Word
    • Future Impact
    • About Us
    • Contact

FAQs

The global colorectal cancer therapeutics market is segmented based on type, drug class, sales channel, top selling drugs, and region.

Rising changes in lifestyle and increasing geriatric population are the major factor driving growth of the global market.

North America is currently dominating the target market because of rising geriatric population, advanced technologies, highest investment in pharmaceuticals and R&D department etc.

The key players operating in the global colorectal cancer therapeutics market includes Pfizer Inc., Teva Pharmaceutical Industries Ltd, Hikma Pharmaceuticals Plc, Amneal Pharmaceuticals Inc., Amgen Inc., Bayer AG, Bristol-Myers Squibb, Eli Lilly and Company, Merck & Co., Inc., Biocon Ltd.